Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trials. Issue 1 (13th November 2014)

• Record Type: Journal Article
• Authors: Letzkus, Martin; Luesink, Evert; Starck‐Schwertz, Sandrine; Bigaud, Marc; Mirza, Fareed; Hartmann, Nicole; Gerstmayer, Bernhard; Janssen, Uwe; Scherer, Andreas; Schumacher, Martin M; Verles, Aurelie; Vitaliti, Alessandra; Nirmala, Nanguneri; Johnson, Keith J; Staedtler, Frank
• Is Part Of: Clinical and translational medicine. Volume 3:Issue 1(2013)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2014-11-13
• Subjects: Cell sorting -- Transcriptomics -- Clinical; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1186/s40169-014-0036-z
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: Background: Clinically useful biomarkers for patient stratification and monitoring of disease progression and drug response are in big demand in drug development and for addressing potential safety concerns. Many diseases influence the frequency and phenotype of cells found in the peripheral blood and the transcriptome of blood cells. Changes in cell type composition influence whole blood gene expression analysis results and thus the discovery of true transcript level changes remains a challenge. We propose a robust and reproducible procedure, which includes whole transcriptome gene expression profiling of major subsets of immune cell cells directly sorted from whole blood. Methods: Target cells were enriched using magnetic microbeads and an autoMACS® Pro Separator (Miltenyi Biotec). Flow cytometric analysis for purity was performed before and after magnetic cell sorting. Total RNA was hybridized on HGU133 Plus 2.0 expression microarrays (Affymetrix, USA). CEL files signal intensity values were condensed using RMA and a custom CDF file (EntrezGene‐based). Results: Positive selection by use of MACS® Technology coupled to transcriptomics was assessed for eight different peripheral blood cell types, CD14+ monocytes, CD3+, CD4+, or CD8+ T cells, CD15+ granulocytes, CD19+ B cells, CD56+ NK cells, and CD45+ pan leukocytes. RNA quality from enriched cells was above a RIN of eight. GeneChip analysis confirmed cell type specific transcriptome profiles. Storing whole blood collected in an EDTA Vacutainer® tube at 4°C followed by MACS does not activate sorted cells. Gene expression analysis supports cell enrichment measurements by MACS. Conclusions: The proposed workflow generates reproducible cell‐type specific transcriptome data which can be translated to clinical settings and used to identify clinically relevant gene expression biomarkers from whole blood samples. This procedure enables the integration of transcriptomics of relevant immune cell subsets sorted directly from whole blood in clinical trial protocols.